We aim to foster a transparent, continuous and trusting dialogue with all capital market participants.
The Zur Rose Group performed in line with revenue expectations in the third quarter of 2022 and will see EBITDA at the upper end of the forecast target range for 2022.
Our newsroom provides you with the latest corporate news and ad hoc press releases.
Get the latest information on market trends, financials and the strategy of the Zur Rose Group.
The Zur Rose Group continued to rigorously pursue its growth strategy in 2021 – in particular seizing the opportunities arising from electronic prescriptions in Germany and internationalisation.
Discover the presentation of our most recent Capital Markets Day.
In our first sustainability report, we disclose current and future trends. This transparency helps us to appreciate our strengths and to identify room for improvement.
The Zur Rose Group is ideally positioned to deliver on the eRx (e-prescription) opportunity in Germany and execute its strategy to build the digital healthcare ecosystem of choice.
Here you can find all financial publications of the Zur Rose Group.
Our financial calendar gives you an overview of communication dates, investor conferences, roadshows and the annual general meeting.
Want to know more? Our Investor Relations team will be glad to answer any questions you may have about the Zur Rose Group share and related capital market topics.
Additional contacts can be found here:
+41 58 810 11 email@example.com